SLC5A2 and cardiovascular disorder: The EASD/European Society of Cardiology (ESC) guidelines recommend pharmacotherapy focusing on agents with proven cardiovascular benefits like SGLT2 inhibitors for patients with T2DM and established cardiovascular disease.